TY - JOUR
T1 - Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
AU - Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
AU - Tada, Toshifumi
AU - Kumada, Takashi
AU - Hiraoka, Atsushi
AU - Atsukawa, Masanori
AU - Hirooka, Masashi
AU - Tsuji, Kunihiko
AU - Ishikawa, Toru
AU - Takaguchi, Koichi
AU - Kariyama, Kazuya
AU - Itobayashi, Ei
AU - Tajiri, Kazuto
AU - Shimada, Noritomo
AU - Shibata, Hiroshi
AU - Ochi, Hironori
AU - Yasuda, Satoshi
AU - Toyoda, Hidenori
AU - Fukunishi, Shinya
AU - Ohama, Hideko
AU - Kawata, Kazuhito
AU - Tani, Joji
AU - Nakamura, Shinichiro
AU - Nouso, Kazuhiro
AU - Tsutsui, Akemi
AU - Nagano, Takuya
AU - Takaaki, Tanaka
AU - Itokawa, Norio
AU - Okubo, Tomomi
AU - Arai, Taeang
AU - Imai, Michitaka
AU - Joko, Kouji
AU - Koizumi, Yohei
AU - Hiasa, Yoichi
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - We investigated the impact on survival of modified albumin–bilirubin (mALBI) grade versus Child–Pugh classification in patients with hepatocellular carcinoma (HCC) who received lenvatinib. A total of 524 patients with HCC who received lenvatinib were included. Univariate analysis showed that mALBI grade 2b/3 and Child–Pugh class B/C were significantly associated with survival [hazard ratio (HR), 2.471; 95% confidence interval (CI), 1.944–3.141 and HR, 2.178; 95%CI, 1.591–2.982]. In patients with a Child–Pugh score of 5, multivariate analysis showed that mALBI grade 2b/3 was independently associated with survival (HR, 1.814; 95%CI, 1.083–3.037). Conversely, among patients with mALBI grade 1/2a, there was no difference in survival between those with a Child–Pugh class of 5 or 6 (p = 0.735). Time-dependent receiver operating characteristic analysis showed that the ALBI score predicted survival better than the Child–Pugh score. The optimal cut-off value of the ALBI score for predicting survival was nearly the same as the value separating mALBI grades 2a and 2b. In conclusion, the mALBI grade was a better predictor of survival than the Child–Pugh classification in patients with unresectable HCC who received lenvatinib therapy.
AB - We investigated the impact on survival of modified albumin–bilirubin (mALBI) grade versus Child–Pugh classification in patients with hepatocellular carcinoma (HCC) who received lenvatinib. A total of 524 patients with HCC who received lenvatinib were included. Univariate analysis showed that mALBI grade 2b/3 and Child–Pugh class B/C were significantly associated with survival [hazard ratio (HR), 2.471; 95% confidence interval (CI), 1.944–3.141 and HR, 2.178; 95%CI, 1.591–2.982]. In patients with a Child–Pugh score of 5, multivariate analysis showed that mALBI grade 2b/3 was independently associated with survival (HR, 1.814; 95%CI, 1.083–3.037). Conversely, among patients with mALBI grade 1/2a, there was no difference in survival between those with a Child–Pugh class of 5 or 6 (p = 0.735). Time-dependent receiver operating characteristic analysis showed that the ALBI score predicted survival better than the Child–Pugh score. The optimal cut-off value of the ALBI score for predicting survival was nearly the same as the value separating mALBI grades 2a and 2b. In conclusion, the mALBI grade was a better predictor of survival than the Child–Pugh classification in patients with unresectable HCC who received lenvatinib therapy.
UR - http://www.scopus.com/inward/record.url?scp=85110880036&partnerID=8YFLogxK
U2 - 10.1038/s41598-021-93794-5
DO - 10.1038/s41598-021-93794-5
M3 - 学術論文
C2 - 34262065
AN - SCOPUS:85110880036
SN - 2045-2322
VL - 11
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 14474
ER -